Orion S.A. (OEC) is experiencing high implied volatility in its October 2026 put options, suggesting traders expect significant price movement. However, the fundamental outlook remains weak, with analysts downgrading earnings estimates for the current quarter from 7 cents to 5 cents per share over the last 60 days. The company holds a Zacks Rank #3 (Hold) rating in the Chemical - Specialty industry.

Orion (OEC) reported Q2 2026 adjusted earnings of 14 cents per share, beating consensus by 27.3%, with net sales rising 7.4% year-over-year to $500.9 million. However, shares have declined 21.5% since the earnings report. The Specialty Carbon Black segment showed strength with 96% EBITDA growth, while Rubber Carbon Black segment EBITDA fell 60.7% due to lower contractual pricing and softer tire production. The company reaffirmed its 2026 adjusted EBITDA guidance of $170-$210 million and raised free cash flow guidance. Analyst estimates have shifted downward 28.57% in the past month, and the stock holds a Zacks Rank #3 (Hold) with a VGM Score of B.

Orion reported Q1 2026 revenue of €417.7 million (+17.8% YoY) and operating profit of €114.8 million (+47.3% YoY). The company raised its 2026 guidance, expecting revenue of €1,950-2,100 million and operating profit of €600-750 million. Growth was driven by Nubeqa® royalties and product sales, Easyhaler® portfolio success, and strong performance across all business units. ODM-212 received FDA orphan drug designation for mesothelioma and initiated a Phase 1b/2 trial.

Gabelli Funds will host its 17th Annual Specialty Chemicals Symposium on March 19, 2026, in Midtown Manhattan, featuring discussions with leading specialty chemicals companies on industry dynamics and trends. The event will include one-on-one meetings with management teams and webcast access for remote attendees.

Orion reported Q3 2025 net sales of €423.2 million and operating profit of €121.0 million, with growth in most business divisions. The company discontinued ODM-105 insomnia treatment and plans to focus on oncology research and biological candidates.

Orion reported Q3 2025 financial results with a revenue of €423.2 million and operating profit of €121.0 million. The company saw strong growth in basic business, particularly in Nubeqan sales and royalties, while experiencing a decline compared to the previous year due to significant milestone payments in 2024.

Orion reported strong Q2 2025 financial results with 26.9% revenue growth to €416.5 million and 58.9% increase in operating profit to €104.6 million. The company upgraded its full-year outlook, expecting revenue of €1,630-1,730 million and operating profit of €400-500 million.

Orion Oyj has upgraded its financial guidance for 2025, expecting higher revenue and operating profit due to faster-than-anticipated product sales and royalty income in the first half of the year.

Orion and Glykos Finland Oy have expanded their research collaboration and licensing agreement to develop next-generation antibody-drug conjugates (ADCs) for cancer treatment. The expanded agreement gives Orion the right to use Glykos' ADC technologies in three new ADC projects, in addition to the three projects already agreed upon.

Orion and Glykos have extended their research collaboration and licensing agreement for the development of next-generation antibody-drug conjugates (ADCs). Orion will be responsible for the target selection, research, development, and commercialization of up to three new ADC programs, with a focus on solid tumors.

Orion's partner MSD has expanded the clinical development program for opevesostat (MK-5684) to include clinical trials for the treatment of breast, endometrial, and ovarian cancers in women. MSD has exclusive worldwide rights to opevesostat, which was discovered and developed by Orion.

Orion's Q1 2025 revenue grew 14.9% to €354.6 million, and operating profit increased 39.1% to €77.9 million. The company maintained its full-year 2025 guidance, expecting revenue of €1,550-1,650 million and operating profit of €350-450 million.